1. From Conference to Practice: Big Data in Psoriasis

3. This program will include a discussion of investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Description of Program

5. Description of Program

6. Comorbid Diseases Associated With Psoriasis

7. Psoriasis Is a Chronic, Systemic, Inflammatory Disease

8. Cardiovascular Disease

9. Atherosclerotic Disease and Psoriasis

10. Joint Disease

11. Treatments for Psoriatic Arthritis

12. Summary

13. Updates on Topical Therapies

14. Halobetasol (0.01%)/Tazarotene (0.04%): Phase 3 Studies

15. Halobetasol (0.01%)/Tazarotene (0.04%): Efficacy Data

16. Tapinarof: Phase 2 Study

17. Tapinarof Phase 2 Study: Efficacy Data

18. Tofacitinib Topical: Phase 2 Study

19. Tofacitinib Topical Phase 2 Study: Efficacy Data

20. Implications for Practice

21. What’s New in Oral Therapies

22. Considerations Regarding Oral Therapies

23. Apremilast: Long-term Efficacy in Skin Disease

24. Apremilast: Efficacy in Nail Disease

25. Tofacitinib: Efficacy in Nail Psoriasis

26. Tofacitinib: NAPSI Scores at Week 52

27. New Data on TNF Inhibitors

28. Long-term Safety and Efficacy of Adalimumab: ESPIRIT Registry

29. Adalimumab Efficacy: PGA 1/0

30. Certolizumab Pegol

31. Certolizumab Pegol: Efficacy Data

32. TNF Inhibitors and Pregnancy

33. Updates on IL-17 Blockers

34. The New Gold Standard

35. Secukinumab: Long-term Efficacy

36. Ixekizumab: Long-term Efficacy

37. Brodalumab: Long-term Efficacy

38. IL-17 Blockers Are a “Game-Changer”

39. Emerging Data on IL-23 Inhibitors

40. IL-23 in Psoriasis

41. Guselkumab: Phase 3 Efficacy Data

42. Risankizumab: Phase 2 Efficacy Data

43. Tildrakizumab: 2-Year Open-label Extension

44. Implications for Practice

45. Abbreviations

46. Abbreviations (cont)